Galactose 1-phosphate Potassium salt
(Synonyms: 阿尔法-D-半乳糖1-磷酸二钾盐五水合物) 目录号 : GC31493An intermediate in the interconversion of glucose and galactose
Cas No.:19046-60-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
α-D-Galactose-1-phosphate is an intermediate in the interconversion of glucose and galactose. It is produced from galactose by galactokinase. Galactose-1-phosphate uridyl transferase reversibly catalyzes the conversion of UDP-glucose (Item No. 15602 and galactose-1-phosphate to glucose-1-phosphate and UDP-galactose.
Cas No. | 19046-60-7 | SDF | |
别名 | 阿尔法-D-半乳糖1-磷酸二钾盐五水合物 | ||
Canonical SMILES | O=P(O[K])(O[K])O[C@H]1O[C@@H]([C@H](O)[C@H](O)[C@H]1O)CO | ||
分子式 | C6H15K2O11P | 分子量 | 372.35 |
溶解度 | Water : 125 mg/mL (371.67 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.6856 mL | 13.4282 mL | 26.8565 mL |
5 mM | 0.5371 mL | 2.6856 mL | 5.3713 mL |
10 mM | 0.2686 mL | 1.3428 mL | 2.6856 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Hereditary Dystonia Overview
The purpose of this overview on hereditary dystonia is to help clinicians determine if an individual has a hereditary dystonia in order to provide information regarding recurrence risk and evaluation of relatives at risk. Goal 1: Describe the clinical characteristics of dystonia. Goal 2: Review the causes of hereditary dystonia. Goal 3: Provide an evaluation strategy to determine the etiology of hereditary dystonia in a proband. Goal 4: Review the differential diagnosis of hereditary dystonia (i.e., non-genetic causes of dystonia). Goal 5: Provide information regarding recurrence risk and evaluation of relatives of a proband with hereditary dystonia who are at risk.
The C-terminal domain of the Salmonella enterica WbaP (UDP-galactose:Und-P galactose-1-phosphate transferase) is sufficient for catalytic activity and specificity for undecaprenyl monophosphate
Two families of membrane enzymes catalyze the initiation of the synthesis of O-antigen lipopolysaccharide. The Salmonella enterica Typhimurium WbaP is a prototypic member of one of these families. We report here the purification and biochemical characterization of the WbaP C-terminal (WbaP(CT)) domain harboring one putative transmembrane helix and a large cytoplasmic tail. An N-terminal thioredoxin fusion greatly improved solubility and stability of WbaP(CT) allowing us to obtain highly purified protein. We demonstrate that WbaP(CT) is sufficient to catalyze the in vitro transfer of galactose (Gal)-1-phosphate from uridine monophosphate (UDP)-Gal to the lipid carrier undecaprenyl monophosphate (Und-P). We optimized the in vitro assay to determine steady-state kinetic parameters with the substrates UDP-Gal and Und-P. Using various purified polyisoprenyl phosphates of increasing length and variable saturation of the isoprene units, we also demonstrate that the purified enzyme functions highly efficiently with Und-P, suggesting that the WbaP(CT) domain contains all the essential motifs to catalyze the synthesis of the Und-P-P-Gal molecule that primes the biosynthesis of bacterial surface glycans.